Status:
RECRUITING
A Database Survey to Evaluate the Safety of Immune Globulin Subcutaneous (Human), 20% Solution in Participants with Primary Immunodeficiency
Lead Sponsor:
Takeda
Conditions:
Primary Immunodeficiency Diseases (PID)
Eligibility:
All Genders
Brief Summary
This study is a retrospective database study in Japan to evaluate the safety of Immune Globulin Subcutaneous (Human), 20% Solution in participants with primary immunodeficiency disease (PID). This sur...
Eligibility Criteria
Inclusion
- Patients with primary immunodeficiency (PID) enrolled in the PID patient registry.
- Participant for whom study drug is entered in the therapeutic drug field on the data set.
- Participant who is entered the intractable disease diagnosis corresponding to PID in the intractable disease information field.
- Participant for whom the presence or absence of adverse events has been entered in the column of adverse events.
Exclusion
- Participant for whom study drug has not been entered in the drug name in the medical history field during the period from January 24, 2024 to January 23, 2029.
- Participant who is not entered the intractable disease diagnosis corresponding to PID in the intractable disease information field.
- Participant for whom the presence or absence of adverse events has not been entered in the column of adverse events.
Key Trial Info
Start Date :
February 17 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 31 2030
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06565078
Start Date
February 17 2025
End Date
July 31 2030
Last Update
February 20 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Takeda selected site
Tokyo, Tokyo, Japan